Projects per year
Simon Mackay is the Professor of Medicinal Chemistry in the Strathclyde Institute of Pharmacy and Biomedical Science at the University of Strathclyde and has 25 years’ experience of research and teaching in the application of medicinal chemistry to drug discovery. He is a graduate of the University of Bath (BPharm (Hons); 1984) and the University of Manchester (PhD Medicinal Chemistry; 1990). In terms of research, his primary interest is cancer drug discovery, and he is the Principal Investigator for a £3.0M CRUK-funded programme to identify small molecule inhibitors for the treatment of prostate cancer (http://myprojects.cancerresearchuk.org/projects/prostate-cancer), which involves leading and co-ordinating a multidisciplinary team including medicinal chemists, phytochemists, biochemists, pharmacologists and clinicians. This programme has recently been funded by Prostate Cancer UK and MRC. He is also involved in a kinesin drug discovery project with collaborators at UCL to identify new Eg5 inhibitors. He has led the medicinal chemistry team for a number of industry-funded drug discovery projects, including the identification of non-steroidal neuroprotective compounds for Hunter-Fleming, PTP1B inhibitors for Kyorin Pharmaceutical and the £9.3M drug discovery programme targeting the Ubiquitin Proteasome System, funded by Scottish Enterprise.
He is a co-founder of SMSdrug.net (http://www.smsdrug.net), an EPSRC-BBSRC- MRC initiative to establish an academia-Users Network in Chemical Biology to initiate, establish and nurture collaborative projects for the advancement of the drug discovery process. This links with the Drug Discovery Portal (DDP http://www.ddp.strath.ac.uk/), which is a major strategic initiative in international research and knowledge-exchange at the University of Strathclyde that brings together the rich, but currently isolated resources in drug research in academic institutions worldwide and provides an accessible central resource to allow chemists and biologists to boost their current drug discovery research efforts.
Over the past 5 years, he has attracted over £4.8M of external funding on drug discovery projects.
In addition to being a member of the Royal Society of Chemistry and the Royal Pharmaceutical Society, he is on the Expert Advisory Panel for Pharmaceutical Science and the Translational Biology Directorate of the Scottish Universities Life Sciences Alliance. He is the external examiner for degree programmes in drug discovery and phamacy at the University of Edinburgh and Robert Gordons University. He is a member of the Allied Health Professions, Dentistry, Nursing and Pharmacy Panel for the Research Excellence Framework 2014.
Doctor of Philosophy, University of Manchester
Bachelor of Pharmacy, University of Bath
Research Output per year
Inhibitory Kappa B kinase α (IKKα) inhibitors that recapitulate their selectivity in cells against isoform-related biomarkersAnthony, N. G. , Baiget, J. , Berretta, G. , Boyd, M. , Breen, D. , Edwards, J. , Gamble, C. , Gray, A. I. , Harvey, A. L. , Hatziieremia, S. , Ho, K. H. , Huggan, J. K. , Lang, S. , Llona-Minguez, S. , Luo, J. L. , McIntosh, K. , Paul, A. , Plevin, R. J. , Robertson, M. N. , Scott, R. & 4 others , 24 Jul 2017, In : Journal of Medicinal Chemistry. 60, 16, p. 7043-7066 24 p.
Research output: Contribution to journal › Article
Synthetic biological approaches for RNA labelling and imaging: design principles and future opportunitiesPauff, S., Withers, J. M., McKean, I. JW., Mackay, S. P. & Burley, G. A., 1 Dec 2017, In : Current Opinion in Biotechnology. 48, p. 153-158 6 p.
Research output: Contribution to journal › Review article
Student thesis: Doctoral Thesis
Design, synthesis and biological evaluation of sphingosine kinase inhibitors for the treatment of prostate cancerAuthor: Tawati, S. M. A., 1 Dec 2015
Student thesis: Doctoral Thesis